NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Pablo Corral Highlights CRIC Study: Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in CKD
Pablo Corral/Linkedin
Aug 25, 2025, 09:25

Pablo Corral Highlights CRIC Study: Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in CKD

Pablo Corral, Past President of Argentine Lipid Society, has shared a post on Linkedin:

“Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease

New data from the CRIC study

In CKD patients without clinical CVD, aspirin use was associated with 38% lower MI risk and 28% lower ESRD risk — but only when Lp(a) ≥50 mg/dL.

No significant benefit was seen when Lp(a) <50 mg/dL, and bleeding risk did not increase.”

aspirin

Title: Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort

Authors: Alexander C. Razavi, Jing Chen, Wei Yang, Daohang Sha, Omar Dzaye, Harpreet S. Bhatia, Sotirios Tsimikas, James P. Lash, Mayank Kansal, Hernan Rincon-Choles, Viola Vaccarino, Terry A. Jacobson, Matthew J. Budoff, Roger S. Blumenthal, Seamus P. Whelton, Laurence S. Sperling, Michael J. Blaha, Jiang H

Read the full article here.

Read more on  Hemostasis Today.

Alexander C. Razavi Aspirin CRIC study Daohang Sha Harpreet S. Bhatia Health Hemostasis Hemostasis Today Hernan Rincon-Choles James P. Lash Jiang H Jing Chen Laurence S. Sperling Lipoprotein(a) Matthew J. Budoff Mayank Kansal MI Michael J. Blaha Omar Dzaye Pablo Corral Prevention Roger S. Blumenthal Seamus P. Whelton Sotirios Tsimikas Terry A. Jacobson Viola Vaccarino Wei Yang
NewsFeed